An interventional study of puerarin tablet 50 mg and Atorvastatin tablet 20 mg in Rheumatoid Arthritis, sponsored by Chengdu PLA General Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-04.
Sponsored by Chengdu PLA General Hospital · Not applicable, Interventional, and Treatment
To evaluate the Effect of Puerarin tablets versus statins in treating metabolism syndrome in patients with chronic rheumatic diseases
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's planned enrollment of 150 is above the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →Chengdu PLA General Hospital is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients were orally administrated with 50 mg puerarin tablet three times a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
Drug: puerarin tablet 50 mg
Patients were orally administrated with 20 mg Atorvastatin tablet once a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
Drug: Atorvastatin tablet 20 mg
Also known as: C15H10O4254.24
Approval No.: H19990258
Also known as: (3r,5rr)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
Change from baseline in homeostasis model assessment (HOMA-IR)
Time frame: At 0 week, 12 weeks, 24 weeks and 48 weeks
Fasting serum low-density lipoprotein cholesterol (LDL-C)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Fasting serum high-density lipoprotein cholesterol (HDL-C)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
erythrocyte sedimentation rate (ESR)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
C reactive protein (CRP)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Fasting serum total cholesterol (TC)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Fasting serum triglycerides (TGs)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
tumor necrosis factor (TNFα)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
interleukin-8 (IL-8)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
interleukin-1 (IL-1)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
interleukin-6 (IL-6)
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Fasting serum insulin
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Fasting serum glucose
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Kidney function
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
Liver function
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
blood cell count
Time frame: at 0 week, 12 weeks, 24 weeks, 48 weeks
This study is status unknown, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chengdu PLA General Hospital